News – Page 1003 – Endpoints News

Julian Adams manages to complete his $50M IPO at Gamida Cell — at a heavy cost

7 years ago

Esperion’s cholesterol drug clears the last big safety hurdle, turning the corner to the FDA — now the big ...

7 years ago

Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout

7 years ago

Biogen, Eisai releases four-year data on aducanumab; EMA stamps Eidos' aTTR therapy with orphan designation

7 years ago

Longtime Apitope CEO Keith Martin steps down; Clearside Biomedical taps Spark exec as CMO

7 years ago

Ultragenyx stumbles with UX007 PhIII, shares plunge

7 years ago

Carving a pipeline out of troubled Teva, OrbiMed leads $60M launch of new NASH player

7 years ago

Novo-backed Galecto Biotech scores €79 million in Series C funding

7 years ago

Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble

7 years ago

Fight! Trump kicks off a war of words with the drug lobby, proposing to peg Medicare prices to overseas rates

7 years ago

Deborah Dunsire kicks off her new gig as Lundbeck CEO with a key PhIII trial failure

7 years ago

Vertex cleans up its pipeline; FDA grants priority review to Jakafi for GVHD

7 years ago

Biogen, Eisai fight back against accusations their big BAN2401 study was skewed -- but this fight isn't over yet

7 years ago

Milestone Pharma grabs an $80M round as it steams into pivotal trial work, starts outlining commercial structure

7 years ago

FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it

7 years ago

Mixed data doesn't stop this biotech unicorn from plotting a looming PhIII showdown

7 years ago

As talk of drug pricing takes center stage, Amgen slashes Repatha price by nearly 60%

7 years ago

Trump to unveil proposal to reduce prices on doctor-administered drugs as midterms loom

7 years ago

Roche's new, single-dose flu drug gets the green light at a hard charging FDA, breaking into record-setting territory

7 years ago

AbbVie is going for it in cystic fibrosis. But why are they buying the weak Galapagos portfolio in a $245M deal?

7 years ago

Bayer, Orion prostate cancer drug delays spread of disease in PhIII, but can it make a mark in a crowded market?

7 years ago

Our Alzheimer's drug was not a complete bust, says vTv; Xtalpi raises $46M more for AI drug discovery engine

7 years ago

Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure

7 years ago

Hong Kong IPO delivers $421M to Innovent as another one of China's biotech unicorns hauls in big money

7 years ago

First page Previous page 1000 1001 100210031004 1005 1006 Next page Last page